Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ENLV logo ENLV
Upturn stock ratingUpturn stock rating
ENLV logo

Enlivex Therapeutics Ltd (ENLV)

Upturn stock ratingUpturn stock rating
$1.12
Last Close (24-hour delay)
Profit since last BUY-5.88%
upturn advisory
Consider higher Upturn Star rating
BUY since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ENLV (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $10

1 Year Target Price $10

Analysts Price Target For last 52 week
$10Target price
Low$0.81
Current$1.12
high$1.76

Analysis of Past Performance

Type Stock
Historic Profit -53.72%
Avg. Invested days 33
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 28.62M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 2
Beta 0.74
52 Weeks Range 0.81 - 1.76
Updated Date 06/30/2025
52 Weeks Range 0.81 - 1.76
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.66

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -34.24%
Return on Equity (TTM) -60.35%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 7617924
Price to Sales(TTM) -
Enterprise Value 7617924
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.49
Shares Outstanding 23849900
Shares Floating 20949067
Shares Outstanding 23849900
Shares Floating 20949067
Percent Insiders 4.61
Percent Institutions 13.43

Analyst Ratings

Rating 2
Target Price 10
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Enlivex Therapeutics Ltd

stock logo

Company Overview

overview logo History and Background

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company. Founded in 2005, it focuses on developing Allocetra, a cell-based therapy, for the treatment of life-threatening inflammatory and immune conditions.

business area logo Core Business Areas

  • Immunotherapy Development: Focuses on research, development, and commercialization of Allocetra, its lead product candidate.

leadership logo Leadership and Structure

Dr. Oren Hershkovitz serves as CEO. The company has a board of directors overseeing strategic direction and management.

Top Products and Market Share

overview logo Key Offerings

  • Allocetra: Allocetra is an investigational cell-based immunotherapy aimed at treating organ dysfunction and inflammatory conditions associated with various diseases, including sepsis and COVID-19. Given its developmental stage, precise market share and revenue figures are unavailable. Competition includes broad spectrum antibiotics and supportive care for sepsis, and antivirals, anti-inflammatory drugs, and ventilation for COVID-19-related organ dysfunction. Direct competitors are other companies developing advanced therapies for sepsis or severe inflammatory conditions, such as Cytokine Modulators.

Market Dynamics

industry overview logo Industry Overview

The immunotherapy market is experiencing substantial growth driven by advancements in cell therapies and increasing prevalence of immune-related diseases. High unmet need and the potential for breakthrough therapies are key drivers.

Positioning

Enlivex is positioned as an innovator in the cell-based immunotherapy space, specifically targeting severe inflammatory conditions with Allocetra. Its competitive advantage lies in its unique mechanism of action and potential to address unmet needs.

Total Addressable Market (TAM)

The global sepsis therapeutics market is projected to reach billions of USD. Enlivex's position depends on successful clinical trials and regulatory approvals for Allocetra, but the TAM is potentially very large for effective treatments.

Upturn SWOT Analysis

Strengths

  • Novel cell-based immunotherapy approach
  • Focus on addressing unmet medical needs
  • Experienced management team
  • Positive preclinical and early clinical trial data (limited data)

Weaknesses

  • Reliance on single product candidate (Allocetra)
  • Clinical trial risks and regulatory hurdles
  • Limited financial resources compared to larger pharmaceutical companies
  • No products are currently approved or generating revenue.

Opportunities

  • Expansion of Allocetra's application to other inflammatory conditions
  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results leading to regulatory approvals
  • Increased awareness and adoption of cell-based immunotherapies

Threats

  • Failure of clinical trials
  • Regulatory setbacks
  • Competition from established therapies and new entrants
  • Changes in healthcare reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • BMY
  • REGN

Competitive Landscape

Enlivex is a smaller player competing with larger, established pharmaceutical companies. Its advantage lies in its novel technology, but it faces significant challenges in terms of resources and market access. The larger pharmaceutical companies are also developing medications to combat diseases.

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by advancing Allocetra through clinical trials and securing funding.

Future Projections: Future growth depends on successful clinical trials and regulatory approvals for Allocetra, as well as potential partnerships or acquisitions. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include ongoing clinical trials for sepsis and COVID-19-related organ dysfunction and efforts to secure additional funding.

Summary

Enlivex Therapeutics is a high-risk, high-reward clinical-stage company focused on developing Allocetra. Its success hinges on the outcome of clinical trials and regulatory approvals. The company has a novel approach but faces challenges in funding and competition. Positive results from ongoing trials could significantly improve its market position, while setbacks could have a negative impact. The company does not have any revenue as of the moment.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share estimates are approximate and based on available data.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Enlivex Therapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 1995-12-12
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.